4//SEC Filing
Young David 4
Accession 0000897069-24-001606
CIK 0001533743other
Filed
Aug 1, 8:00 PM ET
Accepted
Aug 2, 5:09 PM ET
Size
19.4 KB
Accession
0000897069-24-001606
Insider Transaction Report
Form 4
Young David
DirectorPres. Research & Development
Transactions
- Exercise/Conversion
Common Stock
2024-07-10+644→ 81,187 total - Tax Payment
Common Stock
2024-04-05$2.79/sh−518$1,445→ 80,543 total - Tax Payment
Common Stock
2024-07-10$1.71/sh−282$482→ 80,905 total - Award
Restricted Stock Units
2024-06-28+3,233→ 21,922 totalExercise: $0.00→ Common Stock (3,233 underlying) - Award
Restricted Stock Units
2024-06-28+2,425→ 24,347 totalExercise: $0.00→ Common Stock (2,425 underlying) - Exercise/Conversion
Common Stock
2024-04-05+1,675→ 81,061 total - Award
Restricted Stock Units
2024-06-28+404→ 25,155 totalExercise: $0.00→ Common Stock (404 underlying) - Award
Restricted Stock Units
2024-06-28+404→ 24,751 totalExercise: $0.00→ Common Stock (404 underlying)
Holdings
- 10,786(indirect: By Family Entities)
Common Stock
- 30,985(indirect: By Trust)
Common Stock
- 18,544(indirect: By LLC)
Common Stock
Footnotes (4)
- [F1]Distribution of vested restricted shares.
- [F2]Each Restricted Stock Unit represents a contingent right receive one share of the Issuer's common stock, following its vesting on January 1, 2025.
- [F3]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2025, and one-thirty-sixth each month thereafter until fully vested on January 1, 2027.
- [F4]Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting upon the achievement of certain performance goals.
Documents
Issuer
Processa Pharmaceuticals, Inc.
CIK 0001533743
Entity typeother
Related Parties
1- filerCIK 0001378166
Filing Metadata
- Form type
- 4
- Filed
- Aug 1, 8:00 PM ET
- Accepted
- Aug 2, 5:09 PM ET
- Size
- 19.4 KB